SANF Share Price

Open 74.95 Change Price %
High 75.00 1 Day 0.30 0.40
Low 74.50 1 Week -0.25 -0.33
Close 75.00 1 Month 2.00 2.74
Volume 141 1 Year -3.80 -4.82
52 Week High 80.95
52 Week Low 65.00
SANF Important Levels
Resistance 2 75.46
Resistance 1 75.27
Pivot 74.83
Support 1 74.73
Support 2 74.54
BIT Italy Most Active Stocks
ISP 2.38 2.59%
PMI 0.36 5.88%
PMI 0.36 5.88%
UCG 2.54 2.01%
SPM 0.45 -2.17%
SPM 0.45 -2.17%
TIT 0.76 1.33%
ENEL 3.91 -1.01%
BP 2.28 7.04%
BP 2.28 7.04%
BIT Italy Top Gainers Stocks
PR 0.05 25.00%
PR 0.05 25.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
EEMS 0.09 12.50%
STEF 0.11 10.00%
CVAL 0.38 8.57%
MIC 4.31 7.75%
BIT Italy Top Losers Stocks
ECA 0.04 -20.00%
ECA 0.04 -20.00%
ECA 0.04 -20.00%
AMP 8.97 -7.33%
AMP 8.97 -7.33%
AMP 8.97 -7.33%
AMP 8.97 -7.33%
AMP 8.97 -7.33%
AMP 8.97 -7.33%
AMP 8.97 -7.33%

Sanofi (BIT: SANF)

SANF Technical Analysis 3
As on 8th Dec 2016 SANF Share Price closed @ 75.00 and we RECOMMEND Buy for LONG-TERM with Stoploss of 72.28 & Buy for SHORT-TERM with Stoploss of 71.99 we also expect STOCK to react on Following IMPORTANT LEVELS.
SANF Target for December
1st Target up-side 81.14
2nd Target up-side 84.26
3rd Target up-side 87.37
1st Target down-side 72.26
2nd Target down-side 69.14
3rd Target down-side 66.03
SANF Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website
SANF Address
54, Rue La Bo
Paris, 75008
Phone: 33 1 53 77 40 00
SANF Latest News
EU regulator accepts Sanofi/Regeneron's Dupixent product for review   Reuters   - 08th Dec 16
Lilly threatens Sanofi's dominance in insulin with knockoff drug   Indianapolis Business Journal   - 07th Dec 16
MannKind (MNKD) Announces Completion of $10.2M Insulin Sales Agreement with ...   - 07th Dec 16
Big Pharma, Short on Blockbusters, Outsources the Science   Wall Street Journal   - 06th Dec 16
Sanofi Must Pick Its Battle   Bloomberg   - 06th Dec 16
Sanofi, JHL Biotech strike Rituxan biosimilar pact worth up to $236M   FiercePharma   - 05th Dec 16
Sanofi Partners with JHL to Develop Bios...   Genetic Engineering & Biotechnology News   - 05th Dec 16
Sanofi takes over Warp Drive antibiotic program   FierceBiotech   - 30th Nov 16
Sanofi plant failings could pose issues for 2 expected blockbusters   FiercePharma   - 29th Nov 16
Sanofi Partnership Passes First Test With Delivery of Antibiotic Compounds   Wall Street Journal   - 29th Nov 16
Interactive Technical Analysis Chart Sanofi ( SANF BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Sanofi
SANF Business Profile
Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, and Regulus Therapeutics Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.